These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27348169)

  • 1. DYNAMICS OF OPIOID SUBSTITUTION TREATMENTIN DIFFERENT INITIAL SUBSTANCE USER OPIOID DEPENDENT PATIENTS.
    Todadze Kh; Mosia S
    Georgian Med News; 2016 May; (254):56-61. PubMed ID: 27348169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia.
    Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Utilization of buprenorphine and methadone among opioid users who inject drugs.
    Tsui JI; Burt R; Thiede H; Glick SN
    Subst Abus; 2018 Jan; 39(1):83-88. PubMed ID: 28796591
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in polysubstance use patterns and drug-related outcomes between people who inject drugs receiving and not receiving opioid substitution therapies.
    Betts KS; Chan G; McIlwraith F; Dietze P; Whittaker E; Burns L; Alati R
    Addiction; 2016 Jul; 111(7):1214-23. PubMed ID: 26857811
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-prescribed use of opioid substitution medication: Patterns and trends in sub-populations of opioid users in Germany.
    Schulte B; Schmidt CS; Strada L; Götzke C; Hiller P; Fischer B; Reimer J
    Int J Drug Policy; 2016 Mar; 29():57-65. PubMed ID: 26818083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine.
    Schaub M; Chtenguelov V; Subata E; Weiler G; Uchtenhagen A
    Int J Drug Policy; 2010 May; 21(3):229-33. PubMed ID: 19926271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term self-treatment with methadone or buprenorphine as a response to barriers to opioid substitution treatment: the case of Sweden.
    Richert T; Johnson B
    Harm Reduct J; 2015 Feb; 12():1. PubMed ID: 25889208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retention in Georgia opioid substitution therapy program and associated factors.
    Ruadze E; Todadze K
    Harm Reduct J; 2016 Dec; 13(1):35. PubMed ID: 27931232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial.
    Otiashvili D; Piralishvili G; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE
    Drug Alcohol Depend; 2013 Dec; 133(2):376-82. PubMed ID: 23916321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Benzodiazepine Use in Opioid Maintenance Treatment Programme: Risks and Clinical Outcomes.
    Oliveira C; Filipe R; Meira J; Sampaio L; Teixeira L; Rodrigues J; Nunes I; Tavares J
    Acta Med Port; 2021 Mar; 34(3):209-216. PubMed ID: 33971116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Constipation and other common symptoms reported by women and men in methadone and buprenorphine maintenance treatment.
    Haber PS; Elsayed M; Espinoza D; Lintzeris N; Veillard AS; Hallinan R
    Drug Alcohol Depend; 2017 Dec; 181():132-139. PubMed ID: 29054032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence.
    Lavie E; Fatséas M; Denis C; Auriacombe M
    Drug Alcohol Depend; 2009 Jan; 99(1-3):338-44. PubMed ID: 18824311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memory function in opioid-dependent patients treated with methadone or buprenorphine along with benzodiazepine: longitudinal change in comparison to healthy individuals.
    Rapeli P; Fabritius C; Kalska H; Alho H
    Subst Abuse Treat Prev Policy; 2009 Apr; 4():6. PubMed ID: 19374740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opiate agonist treatment to improve health of individuals with opioid use disorder in Lebanon.
    Ghaddar A; Abbas Z; Haddad R
    Harm Reduct J; 2017 Dec; 14(1):78. PubMed ID: 29216892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early experience with Suboxone maintenance therapy in Hungary.
    Demetrovics Z; Farkas J; Csorba J; Németh A; Mervó B; Szemelyácz J; Fleischmann E; Kassai-Farkas A; Petke Z; Oroján T; Rózsa S; Rigó P; Funk S; Kapitány M; Kollár A; Rácz J
    Neuropsychopharmacol Hung; 2009 Dec; 11(4):249-57. PubMed ID: 20150662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Methadone maintenance therapy as evidence based drug abuse planning in developed countries: can developing countries afford and learn from this experience?
    Nsimba SE
    East Afr J Public Health; 2010 Mar; 7(1):54-7. PubMed ID: 21413573
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancing motivation within a rapid opioid substitution treatment feasibility RCT: a nested qualitative study.
    Ayres R; Ingram J; Rees A; Neale J; Beattie A; Telfer M
    Subst Abuse Treat Prev Policy; 2014 Nov; 9():44. PubMed ID: 25407020
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of pain in an in-treatment sample of opioid-dependent people.
    Nielsen S; Larance B; Lintzeris N; Black E; Bruno R; Murnion B; Dunlop A; Degenhardt L
    Drug Alcohol Rev; 2013 Sep; 32(5):489-94. PubMed ID: 23594352
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in Quality of Life following Buprenorphine Treatment: Relationship with Treatment Retention and Illicit Opioid Use.
    Mitchell SG; Gryczynski J; Schwartz RP; Myers CP; O'Grady KE; Olsen YK; Jaffe JH
    J Psychoactive Drugs; 2015; 47(2):149-57. PubMed ID: 25950595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New psychoactive substances as part of polydrug abuse within opioid maintenance treatment revealed by comprehensive high-resolution mass spectrometric urine drug screening.
    Heikman P; Sundström M; Pelander A; Ojanperä I
    Hum Psychopharmacol; 2016 Jan; 31(1):44-52. PubMed ID: 26763789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.